---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-011954"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:54:58.084013+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis

## Summary
- FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.
- Data presented at Crohn's & Colitis Congress, Jan 25-27, 2024 in Las Vegas.
- Presentation covers models for both Crohn's disease and ulcerative colitis.
- Presentation current as of January 25, 2024; furnished as Exhibit 99.1.

## SEC filing metadata
- accession: 0000950170-24-011954
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000095017024011954/0000950170-24-011954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000095017024011954/onvo-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-011954
- JSON: https://secwatch.observer/filing/0000950170-24-011954.json
- Plain text: https://secwatch.observer/filing/0000950170-24-011954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.